Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Maryland, Baltimore
With
National Institute on Drug Abuse (NIDA)
Drug and alcohol abuse by people with severe and persistent mental illness (SPMI) is one of the most significant problems facing the public mental health system. We have been conducting a project to develop a multifaceted treatment for substance abuse in dual disordered patients (Behavioral Treatment for Substance Abuse in Schizophrenia; BTSAS). Results have shown that the treatment is well-accepted by patients and has a significant effect on drug use. While BTSAS has been effective at retaining subjects and fostering reduced drug use, a major problem that occurred was low rates of engagement. The main purpose of this study is to determine if BTSAS is more effective in reducing drug use than a supportive control treatment and to determine if adding a case management component (Critical Time Intervention; CTI) will increase treatment engagement and retention in BTSAS.
Age
18–55
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
a diagnosis of schizophrenia or schizoaffective disorder or a diagnosis of other severe mental disorder including bipolar disorder, major depression, or severe anxiety disorder (by definition, the patient has worked 25% or less of the past year; and/or the patient receives payment for mental disability)
a diagnosis of current dependence for opiates, cocaine, or marijuana
ability and willingness to attend treatment sessions for 6 months
ability and willingness to provide consent to participate
enrolled in mental health care
You may not be if
documented history of severe neurological disorder or severe head trauma with loss of consciousness
severe or profound mental retardation as indicated by chart review
inability to effectively participate in the baseline assessments due to intoxication or psychiatric symptoms on two successive appointments
had a substantial trial in either intervention of the Evaluation of Behavioral Treatment for Substance Abuse in Schizophrenia protocol (H-20680)
inability to attend group sessions due to transportation or other logistical problems
inability to attend scheduled treatment sessions on a regular basis for any reason, or to appropriately participate in research activities due to behavioral or psychiatric problems
Clareo Health | Behavioral Treatment of Drug Abuse in Severe and Persistent Mental Illness (SPMI) Patients
